Quantitative myasthenia gravis score: Assessment of responsiveness and longitudinal validity

被引：110

作者：

Bedlack, RS

Simel, DL

Bosworth, H

Samsa, G

Tucker-Lipscomb, B

Sanders, DB

机构：

[1] Duke Univ, Med Ctr, Durham, NC 27705 USA

[2] Durham VAMC, Durham, NC USA

来源：

NEUROLOGY | 2005年 / 64卷 / 11期

关键词：

D O I：

10.1212/01.WNL.0000163988.28892.79

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

We prospectively tested the quantitative myasthenia gravis score (QMG) for responsiveness and longitudinal construct validity in 53 patients with myasthenia gravis. Index of responsiveness was high. Longitudinal construct validity was confirmed by the correlation between changes in QMG and manual muscle testing and by a difference in QMG changes across patients that were clinically unchanged, improved, or worse between two visits. Our results support QMG use for assessing clinical change in trials.

引用

收藏

页码：1968 / 1970

页数：3

相关论文

共 7 条

[1] Mycophenolate mofetil for myasthenia gravis: An open-label pilot study [J].

Ciafaloni, E ;

Massey, JM ;

Tucker-Lipscomb, B ;

Sanders, DB .

NEUROLOGY, 2001, 56 (01) :97-99

[2] Improving the responsiveness of rating scales - The challenge of stepping twice into the same river [J].

Cudkowicz, ME ;

Schoenfeld, D ;

Williams, L .

NEUROLOGY, 2004, 62 (10) :1666-1667

[3] MEASURING CHANGE OVER TIME - ASSESSING THE USEFULNESS OF EVALUATIVE INSTRUMENTS [J].

GUYATT, G ;

WALTER, S ;

NORMAN, G .

JOURNAL OF CHRONIC DISEASES, 1987, 40 (02) :171-178

[4] Myasthenia gravis - Recommendations for clinical research standards [J].

Jaretzki, A ;

Barohn, RJ ;

Ernstoff, RM ;

Kaminski, HJ ;

Keesey, JC ;

Penn, AS ;

Sanders, DB .

NEUROLOGY, 2000, 55 (01) :16-23

[5] Mycophenolate mofetil for myasthenia gravis - An analysis of efficacy, safety, and tolerability [J].

Meriggioli, MN ;

Ciafaloni, E ;

Al-Hayk, KA ;

Rowin, J ;

Tucker-Lipscomb, B ;

Massey, JM ;

Sanders, DB .

NEUROLOGY, 2003, 61 (10) :1438-1440

[6] Validity and reliability of two muscle strength scores commonly used as endpoints in assessing treatment of myasthenia gravis [J].

Sharshar, T ;

Chevret, S ;

Mazighi, W ;

Chillet, P ;

Huberfeld, G ;

Berreotta, C ;

Houfani, M ;

Gajdos, P .

JOURNAL OF NEUROLOGY, 2000, 247 (04) :286-290

[7] Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis [J].

Wolfe, GI ;

Barohn, RJ ;

Foster, BM ;

Jackson, CE ;

Kissel, JT ;

Day, JW ;

Thornton, CA ;

Nations, SP ;

Bryan, WW ;

Amato, AA ;

Freimer, ML ;

Parry, GJ ;

Mendell, JR .

MUSCLE & NERVE, 2002, 26 (04) :549-552